Table 2.
Comparison of baseline patient characteristics between those with and without low serum MIG levels upon treatment with atezolizumab and bevacizumab
| CXCL9 low (<333 pg/ml) (N = 34) | CXCL9 high (≥333 pg/ml) (N = 34) | p value | |
|---|---|---|---|
| Age (range), years | 71.5 (31–84) | 72.5 (47–89) | 0.29 |
| Sex | |||
| Male | 28 | 27 | >0.99 |
| Female | 6 | 7 | |
| Etiology | |||
| Viral hepatitis | 13 | 17 | 0.46 |
| NBNC | 21 | 17 | |
| CH | 17 | 16 | >0.99 |
| LC | 17 | 18 | |
| ECOG PS | |||
| 0 | 26 | 28 | 0.77 |
| 1 | 8 | 6 | |
| White blood cell count, mm3 | 4,900 (2700–11800) | 5,300 (1,970–9,300) | 0.39 |
| Neutrophil count, mm3 | 3,308 (1,185–9,971) | 3,270 (1,320–7,440) | 0.43 |
| Lymphocyte count, mm3 | 1,088 (480–2881) | 1,140 (140–2664) | 0.92 |
| NLR | 2.82 (0.84–16.69) | 2.84 (0.98–12.15) | 0.69 |
| Platelet, ×104/µL | 16.0 (6.1–46.4) | 17.0 (3.6–41.3) | 0.45 |
| Prothrombin time, % | 96.3 (35.3–118.4) | 95.9 (42.8–128.0) | 0.41 |
| NH3, µg/dL | 42 (12–136) | 42 (8–98) | 0.37 |
| Albumin, g/dL | 3.8 (2.7–4.8) | 3.7 (3.0–4.8) | 0.90 |
| ALBI grade | |||
| 1 | 12 | 13 | 0.87 |
| 2a | 11 | 12 | |
| 2b | 11 | 9 | |
| AST, IU/L | 39 (19–134) | 53 (14–672) | 0.10 |
| ALT, IU/L | 24 (12–122) | 32 (7–278) | 0.14 |
| Child-Pugh grade | |||
| A | 33 | 32 | >0.99 |
| B | 1 | 2 | |
| Child-Pugh score | |||
| 5 | 18 | 20 | 0.70 |
| 6 | 15 | 12 | |
| 7 | 0 | 1 | |
| 8 | 1 | 1 | |
| AFP, ng/mL | 63.2 (1.8–57125.2) | 182.8 (0.8–200000.0) | 0.37 |
| DCP, mAU/mL | 887 (19–213066) | 938 (21–245000) | 0.31 |
| Maximum intrahepatic tumor size, mm | 24.6 (0–160.0) | 48.5 (0–166.6) | 0.06 |
| More than 50% liver involvement | 4 | 7 | 0.51 |
| Diffuse type | 2 | 8 | 0.08 |
| Hepatic tumors | |||
| 0 | 6 | 4 | 0.43 |
| 1 | 2 | 5 | |
| Multiple | 26 | 25 | |
| BCLC stage | |||
| B | 13 | 10 | 0.61 |
| C | 21 | 24 | |
| Up to seven | |||
| In | 13 | 10 | 0.61 |
| Out | 21 | 24 | |
| Positive for Vp | 8 | 5 | 0.54 |
| Positive for Vv | 0 | 1 | >0.99 |
| Positive for bile duct invasion | 1 | 0 | >0.99 |
| Positive for LN metastasis | 3 | 10 | 0.06 |
| Positive for EHM | 12 | 19 | 0.14 |
| Naive | 9/25 | 7/27 | 0.78 |
| Recurrence | |||
| History of operation | 18 | 15 | 0.63 |
| History of RFA | 9 | 10 | >0.99 |
| History of TACE | 18 | 11 | 0.14 |
| History of HAIC | 0 | 1 | >0.99 |
| History of RT | 5 | 5 | >0.99 |
| History of TKI | 20 | 19 | >0.99 |